Pulmonary Responses to Selective Phosphodiesterase-5 and Phosphodiesterase-3 Inhibitors

Chest

Volumn 125, Issue 2, 2004, Pages 644-651

  Matot, Idit ^a   Gozal, Yaacov ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Milrinone; Phosphodiesterase inhibitor; Pulmonary hypertension; Thromboxane A2; Vasodilation; Zaprinast

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PURINE DERIVATIVE; THROMBOXANE A2; UNCLASSIFIED DRUG; ZAPRINAST;

ANALYSIS OF VARIANCE; ANIMAL; ANIMAL EXPERIMENT; ARTICLE; BREATHING; CAT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; HEART LEFT ATRIUM PRESSURE; INTRALESIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG BLOOD FLOW; LUNG BLOOD VESSEL; LUNG CIRCULATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RANDOMIZATION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THORAX; VASCULAR RESISTANCE; VASODILATATION;

EID: 1242284323     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.2.644     Document Type: Article

References (32)

1. Schoeffler P, Lugnier C, Demesy-Waeldele F, et al. Role of cyclic AMP and cyclic GMP phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. Biochem Pharmacol 1987; 36:3965-3972
2. Cohen AH, Hanson K, Morris K. et al. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996; 97:172-179
3. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338:273-277
4. Frostell CG, Fratacci MD, Wain JC, et al. Inhaled nitric oxide: a selective pulmonary vasodilator reversing pulmonary vasoconstriction. Circulation 1991; 83:2038-2047
5. Rabe KF, Tenor H, Dent G, et al. Identification of PDE isoenzymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994; 266:L536-L543
6. Veyssier-Belot C, Cacoub P. Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension. Cardiovasc Res 1999; 44: 274-282
7. Krowka MJ. Pulmonary hypertension: diagnostics and therapeutics. Mayo Clin Proc 2000; 75:625-630
8. Ziegler JW, Ivy DD, Fox JJ, et al. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol 1995; 269:H473-H479
9. Thusu KG, Morin FC, Russell JA, et al. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am J Respir Crit Care Med 1995; 152:1605-1610
10. Skimming JW, DeMarco VG, Kadowitz PJ, et al. Effect of zaprinast and dissolved nitric oxide on the pulmonary circulation of fetal sheep. Pediatr Res 1996; 39:223-228
11. Nagamine J, Hill LL, Pearl RG. Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension. Crit Care Med 2000; 28:2420-2424
12. Ichinose F, Adrie C, Hurford WE, et al. Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. J Appl Physiol 1995; 78:1288-1295
13. Ichinose F, Adrie C, Hurford WE, et al. Selective pulmonary vasodilation induced by aerosolized zaprinast. Anesthesiology 1998; 88:410-416
14. McMahon TJ, Ignarro LJ, Kadowitz PJ. Influence of zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J Appl Physiol 1993: 74:1704-1711
15. Braner DAV, Fineman JR, Chang R, et al. M&B 22948, a cGMP phosphodiesterase inhibitor is a pulmonary vasodilator in lambs. Am J Physiol 1993; 264:H252-H258
16. Beavo JA, Reifsnyder DH. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990; 11:150-155
17. Hyman AL, Kadowitz PJ, Lippton HL. Methylene blue selectively inhibits pulmonary vasodilator responses in cats. J Appl Physiol 1989; 66:1513-1517
18. Vroom MB, Pfaffendorf M, van Wezel HB, et al. Effect of phosphodiesterase inhibitors on human arteries in vitro. Br J Anaesth 1996; 76:122-129
19. Jeffery TK, Wanstall JC. Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: difference between early and established pulmonary hypertension. J Cardiovasc Pharmacol 1998; 32:213-219
20. Clarke WR, Morray JP, Powers K, et al. Amrinone reduces pulmonary vascular resistance elevated by U46619 in isolated perfused lungs. J Cardiovasc Pharmacol 1991; 18:85-94
21. Ono S, Ueda S, Sakuma T, et al. Relaxation of human isolated pulmonary arteries by amrinone. J Cardiovasc Surg 1996; 37:177-181
22. Hashiba E, Hirota K, Yoshioka H, et al. Milrinone attenuates serotonin-induced pulmonary hypertension and bronchoconstriction in clogs. Anesth Analg 2000; 92:790-794
23. Tanaka H, Tajimi K, Moritsune O, et al. Effect of milrinone on pulmonary vasculature in normal dogs and in dogs with pulmonary hypertension. Crit Care Med 1991; 19:68-74
24. Harbison RG, Lippton HL, Hyman AL, et al. Pulmonary vascular actions of amrinone and milrinone [abstract]. Circulation 1984;70(Suppl II):182
25. Hyman AL, Kadowitz P. Pulmonary vasodilator activity of prostacyclin (PGI2) in the cat. Circ Res 1979; 45:404-409
26. Matot I, Neely CF. Pulmonary vasodilator responses to nicardipine: comparison with other vasodilators. Crit Care Med 1995; 23:1851-1857
27. w-nitro-L-arginine methyl ester in the cat. Circ Res 1992; 70:364-369
28. Brigham KL, Meyrick B. Endotoxin and lung injury. Am Rev Respir Dis 1986; 133:913-927
29. Hoettemeier PC, Watkins WD, Peterson MB, et al. Acute pulmonary hypertension and lung thromboxane release after endotoxin infusion in normal and leukopenic sheep. Circ Res 1981; 50:688-694
30. Malik AB. Pulmonary microembolism. Physiol Rev 1983; 63:114-1207
31. Abrams D, Schultz-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84:e4
32. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension [letter]. N Engl J Med 2000; 343: 1342